摘要
目的探讨蒙脱石散联合双歧杆菌乳杆菌三联活菌片治疗小儿腹泻的临床疗效。方法选取浚县妇幼保健院2014年11月—2015年10月收治的80例小儿腹泻患儿,采用随机数字表法分为观察组和对照组,各40例。两组患儿均给予常规治疗,在此基础上对照组给予蒙脱石散治疗,观察组在对照组的基础上给予双歧杆菌乳杆菌三联活菌片治疗,比较两组患者的临床疗效、症状改善时间(止泻时间、退热时间、腹痛消失时间和排便正常时间)及不良反应发生情况。结果观察组总有效率高于对照组,止泻时间、退热时间、腹痛消失时间和排便正常时间均短于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论蒙脱石散联合双歧杆菌乳杆菌三联活菌片治疗小儿腹泻的临床疗效确切,可缩短症状改善时间,不良反应少。
Objective To discuss the clinical efficacy of montmorillonite powder combined with bifidobacterium lactobacillus sanlian living bacterium in the treatment of infantile diarrhea. Methods A total of 80 cases of children with diarrhea were selected from November 2014 to October 2015 in the Maternal and Child Health Care in Jun County,which were randomly divided into the observation group and the control group,40 cases in each group. Two groups were both given conventional treatment,the control group was given montmorillonite powder on the basis of the conventional treatment,the observation group was given bifidobacterium lactobacillus sanlian living bacterium on the basis of the control group. The clinical efficacy and the time of symptoms relief( antidiarrheal time,cooling time,abdominal pain disappear time and normal defecation time) and the adverse reactions were compared of the two groups. Results The total efficacy rate of the observation group was higher than the control group,the antidiarrheal time,cooling time,abdominal pain disappear time and normal defecation time were shorter than those of the control group,the differences were statistically significant( P < 0. 05). The rate of adverse reactions between the two groups had no significant difference( P > 0. 05). Conclusion Montmorillonite powder combined with bifidobacterium lactobacillus sanlian living bacterium has a exact clinical efficacy in the treatment of infantile diarrhea,it could shorten the symptoms time and make adverse reactions less.
出处
《临床合理用药杂志》
2016年第12期18-19,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
腹泻
蒙脱石散
双歧杆菌乳杆菌三联活菌片
治疗结果
】 Diarrhea
Montmorillonite powder
Bifidobacterium lactobacillus sanlian living bacterium
Treatment outcome